Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 9:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Healthy Infants Clear all
Completed Phase 1Phase 2 Interventional

Project 2 Airway Potential Hydrogen (pH) in Asthma

NCT03617718
View directory record Official record
Conditions
Cystic Fibrosis, Asthma, Severe Persistent Asthma, Healthy
Interventions
Glycine Buffer
Drug
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years to 50 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
2
States / cities
Indianapolis, Indiana • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Sep 24, 2026, 9:32 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Multivalent Group B Streptococcus Vaccine In Healthy Nonpregnant Women And Pregnant Women And Their Infants

NCT03765073
View directory record Official record
Conditions
Group B Streptococcus Infections
Interventions
Multivalent Group B streptococcus vaccine, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
0 Years to 40 Years
Enrollment
1,208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
26
States / cities
Mobile, Alabama • Phoenix, Arizona • Lancaster, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2025 · Synced Sep 24, 2026, 9:32 AM EDT
Completed No phase listed Observational

Lung Function and Structure in Healthy Infants and Infants With Recurrent Wheezing

NCT00507676
View directory record Official record
Conditions
Asthma, Wheezing, Infant
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
2 Months to 2 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 29, 2012 · Synced Sep 24, 2026, 9:32 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline's (GSK)Respiratory Syncytial Virus (RSV)Maternal Unadjuvanted Vaccine in Healthy Pregnant Women (Aged 18 to 40 Years) and Their Infants

NCT04126213
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV MAT 60 µg, RSV MAT 120 µg, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
534 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
13
States / cities
Phoenix, Arizona • Huntington Park, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2021 · Synced Sep 24, 2026, 9:32 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Functional Magnetic Resonance Imaging in Infants

NCT00008814
View directory record Official record
Conditions
Healthy, Infant, Newborn, Diseases
Interventions
Not listed
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
1 Day to 4 Months
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 24, 2026, 9:32 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants

NCT07283770
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-581, Placebo, D-IVA, TEZ
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 20, 2026 · Synced Sep 24, 2026, 9:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of VX-770 on Midazolam and Rosiglitazone and the Effect of Fluconazole on VX-770

NCT01060566
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-770
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Apr 15, 2010 · Synced Sep 24, 2026, 9:32 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants

NCT00444457
View directory record Official record
Conditions
Vaccines, Pneumococcal
Interventions
13-valent Pneumococcal Conjugate Vaccine, 7vPnC
Biological
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
42 Days to 98 Days
Enrollment
1,712 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
78
States / cities
Benton, Arkansas • Conway, Arkansas • Fayetteville, Arkansas + 67 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2012 · Synced Sep 24, 2026, 9:32 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Increasing Infant Preventive Health Service Delivery in an Inner City Population

NCT00221507
View directory record Official record
Conditions
Healthy
Interventions
Reminder-Recall-Outreach, Case Management, Patient Navigator
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
Not listed
Enrollment
823 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2010
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Sep 24, 2026, 9:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Omega-3 Supplementation During Pregnancy on Regulation of Stress

NCT01158976
View directory record Official record
Conditions
Healthy Pregnant Women
Interventions
Docosahexanoic Acid, Placebo
Dietary Supplement · Other
Lead sponsor
University of Chicago
Other
Eligibility
20 Years to 34 Years · Female only
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
2
States / cities
Chicago, Illinois • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 29, 2018 · Synced Sep 24, 2026, 9:32 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended Lower Respiratory Tract Infection Due to Respiratory Syncytial Virus in Healthy Late Preterm and Term Infants (MELODY)

NCT03979313
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
MEDI8897, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
0 Years to 1 Year
Enrollment
3,012 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
66
States / cities
Birmingham, Alabama • Fort Defiance, Arizona • Fayetteville, Arkansas + 59 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2024 · Synced Sep 24, 2026, 9:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Relative Bioavailability and Food Effect of a VX-118 Tablet Formulation

NCT06312787
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-118
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 2, 2024 · Synced Sep 24, 2026, 9:32 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of Safety and Immunogenicity of Fluzone® in Healthy Children

NCT00831675
View directory record Official record
Conditions
Influenza
Interventions
Influenza Vaccine 2004-2005 Paediatric Formulation
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 35 Months
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Sep 24, 2026, 9:32 AM EDT
Completed No phase listed Observational

Infant s Examination and Manipulation of Objects

NCT00053469
View directory record Official record
Conditions
Healthy, Infant
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Up to 2 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Sep 24, 2026, 9:32 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Gastrointestinal Tract Microbiome in Healthy Term Infants Receiving Mother'S-own Breast Milk or Cow's Milk-based Infant Formulas

NCT04059666
View directory record Official record
Conditions
Gastrointestinal Microbiome
Interventions
Investigational, Control
Other
Lead sponsor
Mead Johnson Nutrition
Industry
Eligibility
7 Days to 18 Days
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
5
States / cities
Birmingham, Alabama • Altamonte Springs, Florida • Owensboro, Kentucky + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2022 · Synced Sep 24, 2026, 9:32 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Study of Body Composition Methodology in Young Children (InfantPod)

NCT00730587
View directory record Official record
Conditions
Healthy
Interventions
Not listed
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
5 Months to 3 Years
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jan 6, 2016 · Synced Sep 24, 2026, 9:32 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Healthy Term Infants Fed Milk-Based Formulas

NCT01617889
View directory record Official record
Conditions
Healthy Term Infant
Interventions
Experimental powdered milk-based infant formula with an alternate fat blend, A powdered milk-based infant formula, standard fat blend
Other
Lead sponsor
Abbott Nutrition
Industry
Eligibility
53 Days to 115 Days
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 14, 2013 · Synced Sep 24, 2026, 9:32 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants

NCT03621670
View directory record Official record
Conditions
Infections, Meningococcal
Interventions
Bexsero (GSK Biologicals' Meningococcal group-B vaccine/ rMenB+OMV NZ), Prevnar13, Pediarix, Hiberix, Rotarix, M-M-R II, Varivax, Placebo (saline water), Prevnar 20
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
1,196 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
56
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 47 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 24, 2026, 9:32 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to <24 Month-old Children and in 2 Month-old Infants

NCT00686075
View directory record Official record
Conditions
Healthy
Interventions
MEDI-534, Cohort 1, Placebo, Cohort 1, MEDI-534, Cohort 2, Placebo, Cohort 2, MEDI-534, Cohort 3, Placebo, Cohort 3, MEDI-534, Cohort 4, Placebo, Cohort 4, MEDI-534, Cohort 5, Placebo, Cohort 5
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
2 Months to 23 Months
Enrollment
1,338 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
51
States / cities
Mobile, Alabama • Bentonville, Arkansas • Little Rock, Arkansas + 44 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2014 · Synced Sep 24, 2026, 9:32 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

CF And Effects of Drugs Mixed Ex Vivo With Sputum for Mucolytic Treatment

NCT01533636
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Sep 24, 2026, 9:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) in Healthy Adult Panelists

NCT06299696
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VNZ/TEZ/D-IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
25 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Woburn, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 15, 2024 · Synced Sep 24, 2026, 9:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a Human Parainfluenza Virus Vaccine (rHPIV3cp45) in Healthy Infants

NCT00308412
View directory record Official record
Conditions
Paramyxoviridae Infections, Virus Diseases
Interventions
rHPIV3cp45, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 36 Months
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 15, 2010 · Synced Sep 24, 2026, 9:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study on Intestinal Gas Symptoms to Evaluate the Effects of Gas Defense in Otherwise Healthy Adult

NCT00881322
View directory record Official record
Conditions
Abdominal Pain, Abdominal Cramps, Flatulence
Interventions
BC-130 (Gas Defense), Placebo
Dietary Supplement
Lead sponsor
Miami Research Associates
Network
Eligibility
18 Years to 75 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 29, 2009 · Synced Sep 24, 2026, 9:32 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Safety and Immunogenicity of Inactivated Influenza Virus Vaccine Among Healthy Children 6-12 Weeks of Age

NCT00242424
View directory record Official record
Conditions
Inactivated Influenza Vaccine
Interventions
2005-2006 trivalent inactivated influenza vaccine
Biological
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
42 Days to 84 Days
Enrollment
1,375 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 27, 2009 · Synced Sep 24, 2026, 9:32 AM EDT